Medicover Calls India a Distraction. KKR Just Paid 5.4x Revenue for It.
- Funds managed by KKR will acquire Medicover India, the 24-hospital multi-specialty operation of Sweden’s Medicover AB, for €1.2 billion (about $1.39 billion). Medicover holds 66.1% of the business and minority shareholders 33.9%. Closing is expected in Q4 2026, subject to regulatory approvals.
- Medicover India generated revenue of €220.5 million on a last-twelve-months basis to 30 June 2026, putting the transaction at roughly 5.4 times revenue. India accounted for 10% of Medicover’s second-quarter revenue. Medicover shares rose around 8% on the announcement.
- Medicover receives gross cash proceeds of €740 million and says the sale lets it concentrate strategically and operationally on Poland, Germany and Romania. Its financial targets are unchanged until completion.
- This is KKR’s second Indian hospital platform inside roughly a year, following its move to take operational control of the oncology chain HCG in 2025, and it exited Max Healthcare in 2022. KKR states it has invested more than $20 billion across healthcare globally since 2004. The agreement comes four days after it agreed to take US medtech supplier Integer private at around $5.7 billion.
Deal read
The same asset is a distraction to one party and a platform to the other. Medicover is selling to concentrate on Poland, Germany and Romania, describing India as something that dilutes focus, while KKR pays roughly 5.4 times revenue for exactly that. Both positions can be correct, because they are solving different problems. An operator running a European core is buying back management attention, which is a scarce resource for a listed company with three home markets. A financial buyer does not need attention, it needs return, and it has no core to protect.
- This is not KKR’s first bet on Indian hospitals, and that changes what it is. It exited Max Healthcare in 2022 and moved to operational control of the oncology chain HCG in 2025. Holding an oncology network and a 24-hospital multi-specialty network in the same market at the same time is not two investments, it is the opening position of a consolidation. The decision worth watching is whether the two are run as separate holdings or brought together, because that is what separates a platform build from a pair of assets, and it will show up in management appointments long before it shows up in a press release.
- The pace is real, but it is not one strategy accelerating. Integer at roughly $5.7 billion on 3 August was a US medtech supplier taken private through KKR’s core private equity strategy, which signals a long hold and a low return hurdle. Medicover India on 6 August is an Asian provider asset out of the India private equity book, a different fund with a different profile. Roughly $7 billion of healthcare in four days across two continents, executed by two teams. Read it as two books clearing simultaneously rather than a single thesis being pressed hard.
- What to watch, including what cannot be known. KKR publishes only a cumulative healthcare figure, more than $20 billion since 2004, and its portfolio page carries neither dates nor deal values, so a 2026 deployment total is not publicly constructible. Judge the pace on announced transactions and nothing else. Then watch the 33.9% minority, because the structure of that stake decides whether €1.2 billion is the final cheque or the first one. And watch the multiple travel: at 5.4 times revenue, this now sits as a reference point every Indian hospital seller will quote for the next eighteen months.